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Remember the Protofibrils
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Harvard Medical School,
65 Landsdowne St., Cambridge, Massachusetts 02139]
Summary
The highly prevalent neurodegenerative diseases
Alzheimer’s (AD), Parkinson’s (PD), and
Amyotrophic Lateral Sclerosis (ALS) have managed
to elude countless efforts directed at understanding
their causative agents and pathogenesis.  Each of
these diseases is characterized by abnormal
protein aggregation under an unknown modi
operandi we have determined to illuminate.  AD
pathology consists of neurofibrillary tangles and β-
amyloid plaques in numerous brain regions, most
importantly the hippocampus.  Our studies have
focused on β -amyloid plaques, and we have
demonstrated that a protofibrillar intermediate
exists in the pathway from monomeric β-amyloid to
fibril and plaque formation.  Our studies of the α-
Synuclein aggregates characteristic of PD, known
as Lewy Bodies, have revealed a protofibrillar
species that may be critical in PD pathogenesis.
Our studies of ALS have focused on superoxide
dismutase-1 (SOD1) because previous studies have
demonstrated that the A4N mutation in SOD1 leads
to increased susceptibility to disease and forms
aggregates within spinal motor neurons but not
fibrils.  We have shown that the SOD1 functions
properly as a dimer and forms aggregates when it
dissociates into monomers.  We subsequently
found a molecule that stabilized the dimer and
prevented  aggregat ion .  These  three
neurodegenerative diseases all refer to common
theme, which is abnormal protein aggregation.  Our
research has led us to support the hypothesis that,
in the cases of PD and AD, a toxic protofibrillar
intermediate is the causative agent in each disease.
Treatment methods aimed at blocking protofibril
formation may prove to be most effective.
Introduction
The neurodegenerative diseases Parkinson’s (PD),
Alzheimer’s (AD) and Amyotrophic Lateral Sclerosis
(ALS) are three of the most prevalent and heavily
studied.  Alzheimer’s alone affects 4.5 million
Americans, 50% of individuals over 85 years old, and
received an estimated $647 billion of funding in 2005
from the American Government1.  Parkinson’s disease
                                                 
*
This paper was written for BIO346 Molecular Neuroscience. In this
assignment, Michael White role-played a noted biologist, Peter Lanzbury,
Jr., and wrote a state–of-the-art review article on Dr. Lansbury’s research
field, as if he were Dr. Siegel himself. He then presented a PowerPoint
seminar as Dr. Lansbury in an annual public student research conference
“NeuroFrontiers” held at Lake Forest College.
affects 1.5 million Americans, and 1 in 100 individuals
over 60 years of age are diagnosed with the disease2 .
Amyotrophic Lateral Sclerosis affects an estimated
30,000 Americans and has an incidence of 2 in 100,000
individuals3.  Together, these diseases represent prime
research targets.The defining characteristics of AD are
dementia and memory loss due to atrophy of
hippocampal neurons located in the medial temporal
lobe.  These neurons are crucial for embedding
memories in cortical regions of the frontal lobe, and
retrieving memories from these long-term storage sites.
Upon autopsy, the AD brain is characterized by
increased size/depth of sulci and widening of the lateral
ventricles.  Familial Alzheimer’s Disease (FAD)
accounts for roughly 10% of all cases and is the result
of the Aβ40 and Aβ42 mutations in the amyloid pre-
cursor protein (APP)4.
The PD Brain consists of neurofibrillary
tangles composed primarily of α-synuclein in structures
called Lewy Bodies4.  These fibrillar deposits are
specific to dopaminergic neurons of the substantia
nigra.  PD is characterized by a motor initiation
deficiency in which the patient has postural deficits and
resting tremor in the hands and other limbs that develop
when substantia nigra atrophy nears ~ 60% 4,6.
ALS is the result of spinal neuron atrophy7.
Degeneration of these motor neurons leads to the
degeneration of skeletal muscles and death within five
years7.  ALS contrasts AD and PD because it
progresses more rapidly and is often found in
adolescents.  The protein involved is known to be the
superoxide dismutase-1 (SOD1) enzyme4.  Similar to
AD and PD, ~20% of ALS cases are the result of SOD1
mutations.  Our research is concentrated on these
mutations and their affects4,7,8.
In common between AD, PD, and ALS is that
all three demonstrate abnormal protein aggregation or
fibrillization.  Through an unknown mechanism, α-
synuclein, β -amyloid, and SOD1 form fibrils and
aggregates that have come to define each disease.
Our lab has set out to determine if it is the protein
aggregates/fibrils, an intermediate in aggregate/fibril
formation, or a deficiency in the degradation of the
relevant protein that causes these diseases.
Alzheimer’s Disease
Biological Basis
The definitive biological basis of AD remains to be
elucidated.  However, Dr. Alzheimer noted the
presence of extra-cellular neurofibrillary plaques that
were later found to be composed of β-amyloid which is
a product of the cleavage of Alzheimer’s Pre-Cursor
Protein (APP) 4.  In addition, he noted intra-cellular
tangles that have recently been found to contain Tau
protein.  These two features of AD occur in conjunction
with disease progression5.  Genetically, two β-amyloid
mutants, Aβ42 and Aβ40, have been implicated in a
causal role in FAD and are the focus of many of our
studies4.
Prior to our research, a definitive biological
mechanism for AD remained unknown, and research
focused mainly on the β -amyloid plaques and
neurofibrillary tangles as the likely disease causing
agents5. Furthermore, the β-amyloid fibrillization
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pathway had not been discovered.  It had been
determined that amyloid plaque formation was
dependent on the monomeric concentration of Aβ5.
Thus, in order for Aβ  fibrils to form, a critical
concentration had to be reached5.  Most importantly, a
modus operandi had not been established for
plaque/fibril formation and no intermediates had been
identified.  Our early research focused specifically on
illuminating the pathway to fibril formation.
Model System of AD
Several model systems are currently referred to for the
study of AD but none express all features characteristic
of human AD.  A transgenic mouse model expressing
one of two known (FAD) mutants, Aβ42 and Aβ40,
produces plaques but not tangles and demonstrates
memory deficiency4.  A second mouse model that was
transgenic for wild type (WT) human β-amyloid has a
non-fibrillar phenotype but retains memory deficits4.
The WT transgenic model provides strong evidence for
a protofibrillar intermediate as the causative agent of
AD that we will subsequently discuss4.
Illuminating the Protofibril
In order to support the current (1993) hypothesis that
fibrils were the AD causative agent, a detailed
understanding of the pathway to fibril formation had to
be achieved5  Therefore, our 1993-1997 experiments
focused on understanding this pathway. Through
atomic force microscopy (AFM), we were able to
observe the transition from monomer to fibril of Aβ40,
Aβ42, and WT in vitro10.  In this experiment, we
discovered the Aβ protofibril10.  Prior to fibril formation,
there was a stable intermediate that elongated over
time to form a fibril, which we named the protofibril10.
Significantly, as protofibril concentration decreased,
fibril concentration increased10.  In addition, Aβ40 was
found to form fibrils at an increased rate compared to
Aβ4210. Future research would contradict this difference
in formation speed9.
Following our discovery of the Aβ protofibril10,
we gathered more evidence to support its existence.  In
vitro, a solution containing Aβ40 protofibrils was used to
study the transition from protofibril to fibril because
Aβ40 had been found to fibrillize slower that Aβ425,11.
Addition of fibrils to the protofibrillar solution led to
immediate formation of amyloid fibrils11.  In contrast,
addition of protofibrils to the protofibrillar solution did
not yield any fibrils for more than 15 days11.  This
experiment showed that fibril formation from protofibrils
could only be seeded by pre-formed fibrils11.  More
importantly, we have demonstrated that protofibrils are
incorporated into fibrils, refracting criticism that
suggests the protofibril is formed as a byproduct of fibril
formation or numerous other alternatives10,11.
The Protofibril
Atomic force microscopy (AFM) provides a three-
dimensional image of a substrate by detecting surfaces
changes on mica or compounds or similar compounds.
We used  AFM to  s tudy  p ro to f i b r i l
assembly/disassembly which are both related to
concentration, temperature, and ionic environment9.
Aβ40 protofibrils elongate as Aβ40 monomer is added
to the ends.  This can be accelerated with an increase
in Aβ40 monomer concentration9.  In contrast to our
previous study, we found Aβ40 and Aβ42 protofibril
elongation to be similar9,10.  Disassembly of the Aβ40
protofibrils occurred upon dilution of the protofibrillar
solution9.  We also found an increase in temperature
and NaCl concentration to coincide with an increase in
protofibril elongation 9.
Quantifying β-Amyloid Pre-Autopsy
The relationship between Aβ-amyloid fibrillization and
AD associated cognitive decline was our most recent
topic of research13.  We hypothesized that a molecule
could be designed to bind Aβ fibrils and be detected by
single proton computed tomography (SPECT), allowing
this relationship to be understood13.  Rhenium
complexes were synthesized containing the dye Congo
Red and found to bind amyloid plaques13.  This could
be a potential break-through in the understanding of AD
pathogenesis and diagnosis because it is low cost and
detectable readily detectable13.
Compilation of our AD studies with those of
competitors has led us to a four-step process for
amyloid fibril formation9.  A competitor found the first
step by determining a small amount, possibly less that
20 Aβ monomer units, spontaneously interacted to form
protofibrils12.  Second, the protofibril elongates by
interacting with other small protofibrils9.  Third, the
protofibril to fibril conversion is due to interaction among
elongated protofibrils9.  Fourth, the Aβ fibril is elongated
when placed in solution containing Aβ monomer11.  This
new model projects much focus upon the Aβ protofibril
as a possible AD causative agent.
Parkinson’s Disease
Biological Basis
The biological basis of PD has yet to be elucidated but
two mutations α-synuclein, A30P and A53T have been
linked to Familial Parkinson’s Disease (FPD) 4.  In
addition, the S18Y mutant in the UCH-L1 enzyme and
mutations in the enzyme parkin are both linked to FPD4.
α-synuclein is known to be the primary component of
the neurofibrillary inclusions called Lewy Bodies4.  The
enzymes UCH-L1 and parkin are known to aid in
degradation of α-synuclein but an exact role has yet to
be determined4.  Our research over the past several
years has focused on understanding the biological
basis of PD and the relationship between Lewy Bodies
and pathogenesis4.  Prior to our research, the two
mutant forms of α-synuclein, A30P and A53T had been
linked to PD and known to be a component of Lewy
Bodies, but the pathway to fibril formation was unknown
as well as any intermediate species16.  Pre-2000
research focused on the “old model” of disease
causation until we discovered a protofibrillar
intermediate (Figure 1) 14.
Model Systems of PD
Several model systems for the study of PD exist but
some are significantly more beneficial than others.
There is a transgenic mouse model that over-expresses
human WT α-synuclein4.  These WT transgenic mice
suffer atrophy of substantia nigra neurons and have
motor initiation deficiency4.  They also contain α -
synuclein aggregates but they do not conform into a
fibrillar structure4.  A line of mice has been established
that expresses both β-synuclein and α -synuclein
resulting in no signs of PD4.  A drosophila model has
been established that is transgenic and expresses WT,
A30P, or A53T4.  The transgenic drosophila phenotype
consists of movement initiation deficiency, atrophy of
substantia nigra neurons, and α-synuclein fibrils4.
A30P & A53T Fibrillization
As of 1998, the relationship between mutant α -
synuclein   and   rate of  fibril  formation  had  yet  to  be
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determined16.  We set out to achieve this through in
vitro analysis of the two α-synuclein mutants and
human WT16.  We found all to have a disordered
conformation in monomeric form in dilute solution16.
Increasing the α-synuclein concentration for either type
led to formation of fibrils16.  Notably, the A53T mutation
was most rapid at fibril formation16.  This finding led us
to hypothesize that A53T accelerated fibril formation
was the cause for FAD16.
The α-Synuclein Protofibril
In vitro, we studied A53T, A30P, and WT in relation to
fibril formation14.  We found monomeric consumption of
A30P to be more rapid than WT and A53T to be more
rapid than both14.  However, a mixture of WT and A30P
to fibrillize slower than unmixed WT and A30P14.
Protofibrillar intermediates were separated from a
solution containing monomers and Fibrils using gel-
filtration chromatography14.  These protofibrils were
analyzed using AFM and determined to have a
spherical conformation14.  Since the mutations cause
changes in the transition from monomer to protofibril
and fibril formation, it is likely that some property such
as resisting transition from protofibril to fibril (A30P) that
PD results14.
Toxicity of the Protofibril
In vitro, we analyzed the rate of fibril formation between
mouse α-synuclein, human WT, A53T, and A30P17.
Mouse α-synuclein formed fibrils most rapidly when it
was alone but upon addition of human WT the process
was dramatically slowed17.
As stated earlier, the transgenic mouse expressing
human WT α-synuclein did not develop fibrils but
demonstrated symptoms of PD4,15.  Thus, this
experiment supports the hypothesis that the toxic agent
of PD is the protofibril17.  It is possible that the
transgenic mouse was unable to form protective fibrils
in the presence of WT and accumulated toxic
protofibrils15,17,. We next decided to study of the α-
synuclein protofibril in hopes of illuminating the role of
the potentially toxic agent18.  We purified α-synuclein
protofibrils to study its reactivity with synthetic
membranes in vitro and found that the protofibrils bind
the membranes as predominantly β -sheet rich
spheres18.  Pores were then formed in the membranes
that resembled those of bacterial toxins18.  Introduction
of monomeric α-synuclein to membranes did not yield
any pores18.  The same result was observed for fibrils
and membrane18.  This study filled several gaps in
knowledge18.  First, the fibril formation pathway was
discovered to contain a protofibril14,18.  Second, a role of
α-synuclein had been demonstrated at the protofibrillar
level (Figure 1)18.
Remember the Substantia Nigra
Neuronal atrophy of PD is localized to the substantia
nigra for unknown reasons4.  We hypothesized that a
library of various molecules could be screened for one
that inhibited the protofibril transition to fibril19.  Our
search resulted in finding 15 molecules that were
theoretically capable of stabilizing the protofibril of
which 14 were catecholamines similar to dopamine19.
Specifically, an oxidized form of dopamine
Monomer Protofibril Fibril
Parkinson’s
Disease
Alzheimer’s
Disease
AD and PD?
α-Synuclein
β-amyloid
New
Old
Old
AD image courtesy of
www.urmc.rochester.edu/neuros
lides/slides/slide194.jpg
PD Image courtesy of
http://medic.med.uth.tmc.edu/edprog/Path/neu
ro2/neu3-74.jpg
Figure 1:  Diagrammatic pathway showing monomeric α-Synuclein and β-amyloid, and the old versus new model for AD and
PD pathogenesis.
The circles represent α-synuclein in its monomeric, protofibrillar, and fibrillar conformations and their possible relations to PD and AD.
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Figure 2:  UCH-L1 Activity and a Model Relating it to the Toxic Protofibril Hypothesis.  Under the toxic protofibril hypothesis, the
disease causing agent is the α-synuclein protofibril, shown here as red circles.  UCH-L1 (Cross shape) is part of the ubiquityl/proteasomal
α-synuclein degradative pathway.  UCH-L1 ligase activity is dependent on a dimeric conformation of the enzyme which adds addition
molecules of ubiquitin (small red dots) to α-synuclein.  Monomeric UCH-L1 (single cross) demonstrates hydrolase activity by
removing/recycling ubiquitin molecules bound to α-synuclein before it enters the Proteasome.  Increase in ligase activity may promote PD
pathogenesis whi le a  inc rease  in  hydrolase act iv i ty  may prevent  PD.  Images courtesy of
http://alzheimer.wustl.edu/adrc2/Research/Neuropathology/images/cerad_sn.bw.gif, retrieved on 22 November 2005
bound the α-synuclein protofibril and prevented the
formation of fibrils19.  It is reasonable to hypothesize
that the dopaminergic substantia nigra neurons are
specific to PD because of their dopamine producing
capabilities19.
Remember the Proteasome
The parkin enzyme functions as part of the
ubiquityl/proteasomal pathway for several intracellular
and membrane bound proteins, including α -
synuclein4,20.  Parkin is a ubiquityl ligase that adds
ubiquitin to O-glycosylated α-synuclein destined for
proteasomal degradation20.  Numerous p a r k i n
mutations have been identified but a direct effect has
yet to be seen20.
Ubiquitin C-hydorlase–L1 (UCH-L1) functions
as part of the ubiquityl/proteasomal degradative
pathway of α-synuclein420,21,4.  UCH-L1 mutants I93M
and S18Y had been identified prior to our research.
I93M was implicated in a significant increase in FPD
development and S18Y a decrease20.  Our research
built off the known UCH-L1 hydrolyzing role of
removing/recycling ubiquitin from α-synuclein allowing
for its degradation20,21 (Figure 2).
We studied UCH-L1 in the I93M and S18Y mutants on
α-synuclein in vitro21.  I93M was known to increase
FAD susceptibility whereas S18Y appeared to protect
against FAD21,20.  Our findings revealed a dual role of
UCH-L1 that directed related to the type of mutation
assessed21.  We found UCH-L1 to have a dimeric
conformational ubiquityl ligase activity, and a
monomeric ubiquityl hydrolase activity21.  An increase in
dimeric ligase function was found to correlate with
increased levels of α-synuclein and the I93M mutant21.
The S18Y mutant was found to reduce dimerization,
decrease ligase activity, and increase hydrolase
activity, resulting in a decrease in α -synuc le in
concentration21.  This study leads to several hypothesis
concerning the role of α-synuclein monomer, protofibril
or fibril degradation and PD4,20,21 (Figure 2).
Return to the Toxic Protofibril
Following our elucidation of the PD protofibril and its
potentially toxic functions, a detailed study of
protofibrillar structure and functions had yet to be
accomplished.  Use of AFM allowed us to research
these unknown protofibrillar characteristics and shed
some light onto a dimly lit species.
α-Synuclein
Proteasome
Substantia Nigra Atrophy and PDSubstantia Nigra Preserved
UCH-L1
Ligase
UCH-L1
Hydrolase
Monomer Protofibril Fibril
56
As mentioned in our 2001 paper, protofibrillar α -
synuclein was found to bind membranes and form
potentially pathogenic pores18,22.  We elaborated on that
study and made several discoveries in protofibril
structure and function.  The spherical and annular
protofibrils were studied in order to determine their
interaction with membranes.  Spherical protofibrils
(A50P, A53T, and WT) bound membranes but annular
forms, monomers, and fibrils did not22.  Most
significantly, a solution containing membrane and
spherical protofibrils led to membrane pore formation
that was imaged with AFM22.  We noted that the pores
formed by the β -sheet rich spherical protofibrils
resembled those of bacterial toxins22.  This provides
further evidence that the spherical protofibril is indeed
to PD causative agent22.  Our observations of the
spherical protofibril have led us to hypothesize that the
PD pathogenesis could result from increased spherical
protofibril concentration resulting from a decrease in
spherical to annular to fibril formation22.
Protofibrils & Cytoplasmic Crowding
Protofibril formation is known to be accelerated in the
A30P and A53T mutants but the majority of PD cases
are sporadic4,16,23.  These early researches lead us to
the later hypothesis that there must be some other
mechanism responsible for accelerating protofibril
formation in WT23.  To fill this gap in knowledge, we
hypothesized that protofibril formation could be
accelerated by crowding the cell with inert material23.  In
vitro, we found an increase in WT protofibril formation
occurred with an increase in concentration of an inert
polymer23.  As mention in our earlier studies, a lag time
exists between monomer to protofibril formation to fibril
formation23.  Our data showed that the lag time for
protofibril formation decreased from 3 days to 1 day
when 5% PEG 20000 (inert polymer) was added23.  An
increase in the magnitude of crowding comparable to
that in our study could feasibly occur in a cellular
environment that had decreased protein degradation,
such as that seen in UCH-L1 dysfunction23.
α & β Synuclein Demonstrate Profound Interactions
The α-synuclein homologue β-synuclein is known to be
78% identical to α-synuclein24.  It has been previously
demonstrated that a double-transgenic mouse
expressing both human α-synuclein and β-synuclein did
not develop any Parkinsonian symptoms indicating that
β-synuclein possibly inhibits the toxic agent of PD24.
We wanted to further support the hypothesis that the
protofibril was the toxic species24.  We hypothesized
that in vitro β -synuclein would inhibit α-synuclein
protofibril formation.  We initially found that both
monomeric homologues formed protofibrils but β-
synuclein protofibrils did not bind and form pores in
vesicles24.  We then mixed monomeric solutions of β-
synuclein and A53T α-synuclein, resulting in inhibition
of A53T protofibril formation24.  This finding further
supported the toxic protofibril hypothesis because the
non-PD phenotype demonstrated in the double-
transgenic mouse aligned with our in vitro data showing
β-synuclein to inhibit A53T protofibril formation24,25.
Remember the N-Terminus
α-synuclein is known to have a seven-conserved amino
acid sequence on its N-terminus containing both A30P
and A53T mutations26.  We studied a plus 2 and minus
2 sequence mutant to elucidate the evolutionary
conservation of these seven amino acids26.  We found
the minus 2 mutant to favor β-sheet formation over α-
helix and the plus 2 mutant to favor α-helical structure.
As demonstrated in earlier studies, the spherical, pore
forming protofibrils are rich in β-sheet, thus the
conserved amino acid sequence may have been
evolutionarily conserved for its α -helical, non-PD
favoring characteristics14,22,26.
Amyotrophic Lateral Sclerosis
Biological Basis
The biological basis of Amyotrophic Lateral Sclerosis
(ALS) has yet to be discovered4.  The pathology of the
disease consists of spinal motor neuron atrophy with
skeletal muscle degeneration in parallel4.  Similar to PD
and AD, Familial ALS is characterized by mutations in
the superoxide dismutase-1 (SOD1) enzyme4,7,8.  SOD1
normally converts superoxides to hydrogen peroxide4.
The protein aggregates found in ALS neurons contain
copious amounts mutant SOD14.  It remains
unknown if WT SOD1 forms aggregates, and if fibrils
are formed4.
The primary model system for ALS research
is the mouse4.  The most important of these models
was a mouse transgenic for a disabled active-site
SOD1 enzyme demonstrated that ALS was not the
result of SOD1 enzymatic activity because the mouse
developed ALS4.
Prior to our research, the SOD1 mutant had
been identified in Familial ALS and the function of the
enzyme was known4,7,8.  However, the mechanism for
mutant SOD1 aggregate formation remained elusive4,27.
SOD1 was known to function as a dimer but further
detailing had not been accomplished4,7.  Our research
was directed at mutant SOD1 and establishing a
pathway for its presence in aggregates7,8.
SOD1 & Aggregation
We studied the he Familial ALS associated mutant
SOD1 A4V which is known to be extremely virulent.
WT SOD1 dimer is more stable than the mutant leading
us to hypothesize that dissociation of the dimer into
monomeric form was somehow involved in ALS
aggregate formation and pathology7.  In order to test
this hypothesis, we introduced a disulfide bridge at
V148C to stabilize the dimer through covalent
modification7.  We found (in vitro) the unmodified A4V
mutant to contain a lesser dimeric concentration
compared to WT indicating that its stability was
decreased7.  Introduction of the disulfide bridge
stabilized the A4V mutant dimer and prevent its
breakdown into monomers and subsequent aggregate
formation7.
Building on our previous finding that
aggregate formation was the result of an unstable A4V
dimer, we screed banks of molecules for ones that
could possibly stabilize the dimer8,7.  We found 15
molecules that stabilized the dimer, four of which
conferred near identical stability to the WT8.  These two
discoveries are potentially critical in the understanding
of ALS8.  We have identified the loss of dimeric function
in SOD1 as a result of the A4N mutation of Familial
ALS and found the resulting monomer to aggregate.  In
relation to AD and PD, pore like aggregates were
observed in A4V mutant SOD1, suggest a possible link
between the three diseases8.  We have also
demonstrated a novel approach toward stabilization of
mutant SOD17,8.
Treatments
Currently, there is no cure for Alzheimer’s, Parkinson’s,
or Amyotrophic Lateral Sclerosis.  As a direct result of
our years worth of research, we believe that the most
effective treatment strategy for Alzheimer’s and
Parkinson’s diseases would be aimed at preventing
protofibril formation27,28.  If protofibrillar formation can be
prevented, than the apparently toxic affects, such as
membrane pore formation, can be prevented along with
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the phenotypical Aβ plaques and α-synuclein Lewy
Bodies27,28.  Parkinson’s treatment may take aim at
several key processes.  Inhibition of UCH-L1 ligase
activity by preventing dimerization would increase
hydrolase activity and increase α - s y n u c l e i n
degradation.  In addition, over expression of β -
synuclein could provide another means for protofibril
repression24.  ALS treatments that focused on using the
compounds noted in our research could stabilize the
SOD1 dimer and prevent dissociation and subsequent
aggregation7,8.  It must be noted that we believe the
pharmaceutical industry to be slowing the progression
of treatment formation.  We believe this is due to our
lack of a complete understanding of the modi operandi
underlying AD, PD, and ALS27.  Penicillin and aspirin
were developed before their effective mechanism had
been developed.  The same applies for AD, PD, and
ALS27.
Conclusion
Alzheimer’s, Parkinson’s, and Amyotrophic Lateral
Sclerosis represent  the most  prevalent
neurodegenerative disorders4.  Despite all of our
research efforts over the past decade, each disease
remains terminal.  Our research has closely portrayed
AD and PD in that a potentially toxic protofibril was
identified and the beginnings of its functions
illuminated4.  All of our AD and PD studies have
returned to the protofibril its β-sheet rich pore forming
structure4.  Though we identified an aggregate structure
similar to that of the AD and PD protofibrillar pores,
more research will need to be done to determine the
properties of this the SOD1 aggregate7,8.  Early 1990’s
AD and PD research began with the assumption that
the toxic agent was the plaque or Lewy Body because
they were found upon autopsy5.  In the years since this
hypothesis was widely accepted, a new toxic protofibril
hypothesis has emerged and future research appears
to be in that direction4.
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